Menu
Recruiting NCT07241195

A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes

Observational NAFLD and NASH NAFLD( Non-alcoholic Fatty Liver Disease ) NAFLD Cirrhosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease ), NAFLD Cirrhosis. Basic parameters: 65 years — 100 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Study on the Construction of Disease Cohort for Fatty Liver in the Elderly and Its Prevention and Treatment Strategies

Overview

To establish a cohort of elderly fatty liver disease based on the community medical examination population. Through the large-scale cohort study, the risk factors affecting fatty liver in the elderly will be explored in depth from the aspects of lifestyle, environment and genetics, the development pattern and mechanism of fatty liver in the elderly will be analysed, and the health risk assessment system and Chinese standard for fatty liver in the elderly covering cardiovascular risk, risk of hepatic fibrosis and risk of sarcopenia will be established, so as to provide the scientific basis for the precise intervention of fatty liver in the elderly in China.

Primary outcome measures

  • Incidence of liver fibrosis [Time frame: 2 years]
Secondary outcome measures (2)
  • Incidence of cardiovascular disease [Time frame: 2 years]
  • Incidence of sarcopenia [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • ① Elderly people aged ≥65 years among permanent residents (living for more than 5 years) in the survey area;
  • Imaging diagnosis (ultrasound or FibroScan/FibroTouch) of fatty liver; -③ Voluntary participation in this study and signing an informed consent form.

Exclusion criteria

  • ①Major disability, mental illness, major wasting disease, severe cardiac, pulmonary and renal insufficiency;
  • Patients with combined primary liver cancer or other types of cancer; -③Patients who have received liver transplant or other organ transplants.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

China · 1 center
  • NO.518 Shangtang Road — Hangzhou

Identifiers

NCT: NCT07241195 · SJP20250401

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗